Scrip regularly covers business development and deal making in the biopharmaceutical industry. Asia Deal Watch is supported by deal intelligence from Biomedtracker.
Asia Deal Watch: Otsuka Lands Second Alliance With Ionis, Focused On ALS Subpopulation
Plus deals involving Zai Lab/Pfizer, Laekna/Lilly, Takeda/Alloy, Lunit/AstraZeneca, VelaVigo/Avenzo, Biosion/Aclaris, HCW/WY Biotech, Celltrion/iQone and Kaken/Numab.
More from Deal Watch
• By
Plus deals involving GV20/Mitsubishi Tanabe, Kaken/Alumis, AstraZeneca/Alteogen and deal terminations involving Clover/Gavi Alliance and Rhythm/RareStone.
• By
Plus deals involving Relmada/Trigone, Alvotech/Xbrane, OPKO Health/Entera, iOncologi/TargImmune and more.
• By
Plus deals involving Hyundai/Pharma/Avelos, Yuhan/Boehringer Ingelheim, SciClone/Eisai, Viatris/Nxera/Idorsia, Nxera/Holling and Takeda/BridGene.
• By
Vertex, Sanofi, Hansoh and BMS/Myokardia have also recently exited deals. Callio launched with ADC technology from Hummingbird, plus more deals and tech transfer.